Vaxart Future Growth

Future criteria checks 2/6

Vaxart is forecast to grow earnings and revenue by 35.5% and 50.3% per annum respectively while EPS is expected to grow by 42.1% per annum.

Key information

35.5%

Earnings growth rate

42.1%

EPS growth rate

Biotechs earnings growth	21.1%
Revenue growth rate	50.3%
Future return on equity	n/a
Analyst coverage	Low
Last updated	20 Mar 2024

Recent future growth updates

Recent updates

Vaxart oral COVID-19 pill vaccine candidate induces long-lasting antibodies against SARS-CoV-2

Jul 20

Vaxart says recent CRO agreement 'may be integral' to oral COVID vaccine success

Jul 07

Vaxart: A Unique Vaccine Concern

Jun 14

Vaxart: A Speculative Biotech With Potential As Covid-19 Play And Oral Vaccine Platform

Feb 26

Vaxart: Investment Case For An Oral COVID Vaccine Not So Hard To Swallow

Dec 09

Vaxart: Differentiated Covid Oral Route Remains Viable

Nov 16

Vaxart: A Close Look At Their COVID-19 Oral Tablet Vaccine Program

Oct 30

Vaxart: An Update

Oct 02

Companies Like Vaxart (NASDAQ:VXRT) Are In A Position To Invest In Growth

Aug 25

Vaxart: World's First Oral COVID Vaccine In Development

Jul 25

FDA is set to decline new emergency use authorizations for COVID-19 vaccines

May 26

We're Hopeful That Vaxart (NASDAQ:VXRT) Will Use Its Cash Wisely

May 11

Enrollment underway in Vaxart's early-stage norovirus trial in elderly population

May 07

Vaxart EPS misses by $0.04, misses on revenue

May 03

Plucky Underdog Vaxart Still Banging Drum For Oral Vaccination

Apr 30

Vaxart is soaring on more than 10 times the two-month average volume

Apr 27

Shareholders Are Thrilled That The Vaxart (NASDAQ:VXRT) Share Price Increased 231%

Mar 03

Earnings and Revenue Growth Forecasts

NasdaqCM:VXRT - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	68	-62	-60	N/A	2
12/31/2025	23	-81	-63	N/A	3
12/31/2024	15	-78	-59	N/A	3
12/31/2023	7	-82	-72	-70	N/A
9/30/2023	4	-89	-92	-86	N/A
6/30/2023	2	-101	-93	-86	N/A
3/31/2023	1	-108	-104	-94	N/A
12/31/2022	0	-108	-104	-95	N/A
9/30/2022	0	-105	-88	-81	N/A
6/30/2022	0	-93	-87	-81	N/A
3/31/2022	0	-80	-74	-68	N/A
12/31/2021	1	-70	-65	-60	N/A
9/30/2021	1	-64	-60	-55	N/A
6/30/2021	1	-54	-54	-50	N/A
3/31/2021	2	-47	-39	-37	N/A
12/31/2020	4	-32	-25	-24	N/A
9/30/2020	8	-25	-17	-17	N/A
6/30/2020	8	-22	-12	-12	N/A
3/31/2020	7	-19	-12	-12	N/A
12/31/2019	10	-19	-14	-13	N/A
9/30/2019	8	-17	-16	-15	N/A
6/30/2019	8	-18	-17	-16	N/A
3/31/2019	8	-22	-10	-9	N/A
12/31/2018	4	-18	-15	-15	N/A
9/30/2018	3	-15	-12	-11	N/A
6/30/2018	4	-12	-8	-8	N/A
3/31/2018	5	-7	-17	-16	N/A
12/31/2017	6	-12	-10	-10	N/A
9/30/2017	9	-16	N/A	-9	N/A
12/31/2016	8	-19	N/A	-12	N/A
12/31/2015	0	-22	N/A	-15	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: VXRT is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: VXRT is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: VXRT is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: VXRT's revenue (50.3% per year) is forecast to grow faster than the US market (7.9% per year).

High Growth Revenue: VXRT's revenue (50.3% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if VXRT's Return on Equity is forecast to be high in 3 years time

Discover growth companies

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Vaxart Future Growth

Future criteria checks 2/6

Key information

Recent future growth updates

Consensus revenue estimates increase by 57%

Consensus revenue estimates decrease by 60%, EPS upgraded

Consensus EPS estimates upgraded to US$0.77 loss, revenue downgraded

Price target decreased to US$7.75

Consensus revenue estimates fall by 12%

Price target decreased to US$9.75

Recent updates

Now 27% overvalued after recent price rise

Vaxart, Inc. to Report Fiscal Year 2023 Results on Mar 14, 2024

Vaxart, Inc. Announces Chief Executive Officer Changes

Nasdaq Notifies Vaxart's Eligibility for an Additional 180-Day Compliance Period, or Until July 15, 2024, to Regain Compliance with the Bid Price Requirement

Vaxart, Inc. Announces CEO Changes

Vaxart, Inc. has filed a Follow-on Equity Offering in the amount of $10 million.

Vaxart, Inc. Announces Last Subject Dosed in Phase 1 Trial of Its Norovirus Vaccine Candidate in Lactating Mothers

Consensus revenue estimates increase by 57%

Here's Why Vaxart (NASDAQ:VXRT) Must Use Its Cash Wisely

Vaxart Doses First Subject in Phase 1 Trial of its Norovirus Vaccine Candidate in Lactating Mothers

Vaxart, Inc. to Report Q3, 2023 Results on Nov 02, 2023

New minor risk - Market cap size

Vaxart Announces Topline Data from the Phase 2 Challenge Study of Its Monovalent Norovirus Vaccine Candidate

New major risk - Revenue and earnings growth

Vaxart, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Vaxart Receives Written Notice from the Listing Qualifications Department of the Nasdaq Regarding Non-Compliance with the $1.00 Minimum Bid Price Requirement

Vaxart, Inc. Announces Positive Preliminary Topline Data from Dose-Ranging Phase 2 Study of its Bivalent Norovirus Vaccine Candidate

Vaxart (NASDAQ:VXRT) Will Have To Spend Its Cash Wisely

Vaxart, Inc.(NasdaqCM:VXRT) dropped from Russell 2000 Dynamic Index

New major risk - Share price stability

Vaxart, Inc. Announces Last Subject Dosed in Phase 2 Trial of Its Bivalent Norovirus Candidate, and All Subjects Challenge Study of Monovalent Norovirus Candidate

Consensus revenue estimates decrease by 60%, EPS upgraded

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Consensus EPS estimates upgraded to US$0.77 loss, revenue downgraded

Full year 2022 earnings: EPS in line with expectations, revenues disappoint

Vaxart, Inc. Doses First Subject in the Phase 2 Clinical Trial of Its Bivalent Norovirus Candidate

Vaxart, Inc. Names Phillip Lee as Chief Financial Officer

Price target decreased to US$7.75

High number of new and inexperienced directors

Third quarter 2022 earnings released: US$0.23 loss per share (vs US$0.14 loss in 3Q 2021)

Vaxart, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Vaxart: The Market Still Isn't Buying Oral Vaccine Thesis

Vaxart, Inc. Announces Positive Top-line Phase II Clinical Study Data Demonstrating Safety and Immunogenicity of Its Wuhan S-Only COVID-19 Pill Vaccine Candidate

Vaxart, Inc. Appoints Ray Stapleton as Chief Technology Officer

Ray Stapleton joins Vaxart as CTO

Vaxart, Inc. Announces Board Changes

Consensus revenue estimates fall by 12%

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Vaxart, Inc. Appoints W. Mark Watson to Its Board of Directors

Price target decreased to US$9.75

Vaxart shareholders approve proposal to increase number of shares

Vaxart continues to lobby shareholders to vote to increase number of shares

Vaxart, Inc. to Report Q2, 2022 Results on Aug 08, 2022

Vaxart, Inc. Publishes Clinical Data Suggesting its Oral COVID-19 Pill Vaccine Candidate Induces Long-Lasting Mucosal Immune Responses that are Highly Cross-Reactive

Vaxart oral COVID-19 pill vaccine candidate induces long-lasting antibodies against SARS-CoV-2

Vaxart says recent CRO agreement 'may be integral' to oral COVID vaccine success

Vaxart: A Unique Vaccine Concern

Vaxart, Inc. Presents New Preclinical Data Demonstrate Two of it's COVID-19 Vaccine Candidates Protect Against Omicron

Vaxart Reports Positive Preliminary Data from the Phase 1b Trial of its Oral Norovirus Vaccine Candidates in Elderly Adults

Vaxart Announces the Publication of Studies in the Peer-Reviewed Journal Science Translational Medicine That Suggest Mucosal Immunization Could Decrease SARS-CoV-2 Transmission

Price target decreased to US$11.40

Consensus revenue estimates fall by 82%

Vaxart, Inc. Announces Management Changes

First quarter 2022 earnings: EPS and revenues miss analyst expectations

No longer forecast to breakeven

Price target decreased to US$11.60

High number of new and inexperienced directors

Margaret Echerd Notifies as Senior Vice President and Principal Accounting Officer of Vaxart, Inc, Effective as of May 5, 2022

Price target decreased to US$12.00

Consensus forecasts updated

Full year 2021 earnings: EPS and revenues miss analyst expectations

Vaxart: A Speculative Biotech With Potential As Covid-19 Play And Oral Vaccine Platform

Vaxart, Inc. Appoints Edward B. Berg as Senior Vice President and General Counsel

Forecast to breakeven in 2024

Vaxart to Test Cross-Reactivity of Its Covid-19 Oral Tablet Vaccine Against Omicron

Vaxart: Investment Case For An Oral COVID Vaccine Not So Hard To Swallow

Vaxart, Inc. (NasdaqCM:VXRT) acquired KindredBio's manufacturing equipment and GMP manufacturing facility in California from Kindred Biosciences, Inc.

No longer forecast to breakeven

Vaxart: Differentiated Covid Oral Route Remains Viable